Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01805713 · ClinicalTrials.gov registry record

Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung

A clinical trial, sponsored by University of Minnesota.

Completed
Registry status
150
Enrollment target

NCT01805713 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01805713 has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
150 participants
Enrollment target

Study Summary

Cystic fibrosis (CF) is the most common autosomal recessive genetic disease in Caucasians. It results in lung disease that affects quality of life and causes early death. Lung damage from CF starts in infancy and continues over time. Lung damage can negatively affect how the lung functions. It would be ideal to measure lung damage in CF patients in three instances: (1) During the first year of life after diagnosis by state newborn screening programs, (2) In children and adults over long periods of time (years), and (3) During times of illness (pulmonary exacerbation), to allow for better treatment and therapy to prevent loss of lung function. The lung is made of elastin, collagen and cartilage. When the lung is damaged by CF, these components break down into pieces that can be measured in urine, sputum and blood. These products may represent markers of lung injury. We believe that the levels of these markers will be increased over time in CF patients and even higher in patients who are sick with lung symptoms. The goal of my research is to measure the amount of lung breakdown products in urine, sputum and blood in infants, children and adults with CF during times when well and also during times of illness. I also hope to use new technologies involving the study of proteins and metabolites in samples like sputum, urine and blood to help provide new information regarding CF lung disease. These studies will help us to better treat CF lung disease.

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2012-12
Est. Completion 2017-12

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT01805713

The ClinicalTrials.gov registry entry for NCT01805713 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01805713 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01805713 about?

NCT01805713 is a clinical study titled "Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung". Cystic fibrosis (CF) is the most common autosomal recessive genetic disease in Caucasians. It results in lung disease that affects quality of life and causes early death. Lung damage from CF starts in infancy and continues over time. Lung damage can negatively affect how the lung functions. It would...

What is the current status of trial NCT01805713?

This trial is currently completed. The enrollment target is 150 participants. The study started on 2012-12. Estimated completion is 2017-12.

Who is sponsoring clinical trial NCT01805713?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.